1. The glutamatergic dysfunction hypothesis for schizophrenia;Coyle;Harv. Rev. Psychiatry,1996
2. The role of excitatory amino acids in neuropsychiatric illness;Javitt;J. Neuropsychiatry Clin. Neurosci.,1990
3. Recent advances in the phencyclidine model of schizophrenia;Javitt;Am. J. Psychiatry,1991
4. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses;Krystal;Arch. Gen. Psychiatry,1994
5. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors;Javitt;Biol. Psychiatry,1999